A

TLANTA — It’s CAR-T Sunday at the American Society of Hematology’s annual meeting, where researchers representing Gilead Sciences (GILD), Novartis (NVS) and Bluebird Bio (BLUE) are addressing the assembled media horde.

Here’s your quick summary: The complete remission rate to Gilead’s Yescarta remains durable after more than one year of follow up. There are no surprises in the details from the previously announced (and positive) JULIET study of Novartis’ Kymriah in aggressive lymphoma. And the updated overall response to Bluebird’s BB2121 in multiple myeloma is now one patient short of 100 percent. No longer perfect, but very close.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.